Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma

NCT07460362 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

43

Enrollment

OTHER

Sponsor class

Conditions

MCL
Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Interventions

DRUG: Glofitamab
DRUG: Lenalidomide

Sponsor

Peking University Third Hospital